CEO PRESSES CONGRESS FOR BIOLOGICS APPROVAL PATHWAY

JULY 01, 2007

Leaders of the generic drug industry called on Congress to create a new pathway for expeditious approval of generic biologics or "biosimilars," a step they said would translate into significant savings for Americans afflicted with the diseases of the 21st century. Testifying on behalf of the Generic Pharmaceutical Association, Barr Pharmaceuticals Chief Executive Officer (CEO) Bruce Downey urged the House Subcommittee on Health to "open the door for generic and other manufacturers to provide affordable access to many of the lifesaving biological medicines used in the treatment of diabetes, cancer, rheumatoid arthritis, HIV/AIDS, and other diseases."

Currently, these treatments are priced so high that they are out of reach for many patients. For instance, biologic drugs for multiple sclerosis range in price from $16,000 to $25,000 a year, while the rheumatoid arthritis and psoriasis medicine etanercept (Enbrel) costs an average of $16,000 a year per patient.

"What becomes frightening from the cost perspective is that not only are the costs of biological treatments getting more expensive each year, but the utilization of these medicines is growing as well," Downey said. "



SHARE THIS SHARE THIS
0

Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.